Cliff Asness’s Mirum Pharmaceuticals MIRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.35M Sell
28,647
-3,144
-10% -$316K ﹤0.01% 2271
2026
Q1
$2.94M Sell
31,791
-694
-2% -$65.3K ﹤0.01% 2096
2025
Q4
$2.57M Buy
32,485
+1,090
+3% +$78.2K ﹤0.01% 1977
2025
Q3
$2.3M Sell
31,395
-16,121
-34% -$1.02M ﹤0.01% 1896
2025
Q2
$2.42M Sell
47,516
-1,560
-3% -$69.5K ﹤0.01% 1670
2025
Q1
$2.21M Buy
49,076
+37,028
+307% +$1.75M ﹤0.01% 1554
2024
Q4
$498K Sell
12,048
-497
-4% -$20.7K ﹤0.01% 2252
2024
Q3
$489K Buy
12,545
+4,251
+51% +$170K ﹤0.01% 2179
2024
Q2
$284K Sell
8,294
-23,721
-74% -$622K ﹤0.01% 2291
2024
Q1
$804K Buy
32,015
+19,139
+149% +$526K ﹤0.01% 1784
2023
Q4
$380K Sell
12,876
-2,667
-17% -$80.7K ﹤0.01% 1990
2023
Q3
$491K Buy
15,543
+3,317
+27% +$90.8K ﹤0.01% 1846
2023
Q2
$316K Sell
12,226
-2,320
-16% -$61.7K ﹤0.01% 1923
2023
Q1
$349K Buy
14,546
+247
+2% +$5.63K ﹤0.01% 1898
2022
Q4
$279K Buy
14,299
+3,579
+33% +$70.7K ﹤0.01% 1996
2022
Q3
$225K Buy
+10,720
New +$258K ﹤0.01% 2019

Other funds holding MIRM

Cliff Asness's MIRM Position: Q2 2026 in Review

Cliff Asness reduced its Mirum Pharmaceuticals (MIRM) stake by 9.9% in Q2 2026, selling an estimated $316K and leaving 28,647 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

Cliff Asness first reported a position in MIRM in Q3 2022 and has held it in 16 quarters since. 326 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Cliff Asness held 28,647 shares of Mirum Pharmaceuticals worth $3.35M as of Q2 2026.
  • Cliff Asness sold 3,144 Mirum Pharmaceuticals shares in Q2 2026, an estimated $316K.
  • Mirum Pharmaceuticals made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2271 holding.
  • Cliff Asness first reported a position in Mirum Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 326 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.